Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18, 2025 at 5:00 p.m. GMT (12:00 p.m. EST).
The live event and replay will be available via the company’s Events page on its investor website: https://investors.lexpharma.com/.
Positive
- None.
Negative
- None.
News Market Reaction – LXRX
In the Nov 11 session, LXRX gained 9.86%, reflecting a notable positive market reaction. Argus tracked a peak move of +7.1% during that session. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
THE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 5:00 p.m. GMT (12:00 p.m. EST).
The live events and replays of the presentations can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit www.lexpharma.com.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
